BTSG

Analyst Note: BTSG (BrightSpring Health Services, Inc.)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• State: Actionable (Forming Coil)
• Conservative Entry: Not yet triggered. A conservative entry requires a confirmed close above the breakout level (resistance) with volume confirmation.
• Breakout Level: Not yet defined in the provided data stream; this will be established as the resistance level the price attempts to breach.
• Current Price: $66.25
• Extension: Not applicable (price is within the consolidation range, not extended above the breakout).
• ATR Context: Current ATR is 3.1% (productive). This volatility is within the historical "sweet spot" (4–6% is ideal, but 3.1% indicates active, tradable movement without the extreme risk of >8% noise).

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Macro Context: There is no named secular thesis attached to this specific setup as of 2026-06-13. The investment case is not driven by a broad macro narrative (e.g., "Silver Bullet" or "Secular Growth") but is strictly a function of the structural price setup quality combined with the company's fundamental execution.
• Judgment Criteria: The conviction must be derived entirely from the quality of the price structure (the forming coil) and the strength of the underlying business fundamentals reported in the most recent earnings and filings. No external macro assumptions should be injected to bolster the thesis.

3. Business Overview

BrightSpring Health Services, Inc. operates as a leading home and community-based healthcare services platform. The company delivers complementary pharmacy and provider services to complex patients, primarily serving Medicare, Medicaid, and commercially-insured populations.

• Operational Scope: As of the latest filings, the company spans all 50 states, serving over 465,000 patients daily through approximately 10,500 clinical providers and pharmacists.
• Revenue Composition (Management Expectations for 2026):
• Total Revenue: Management expects full-year 2026 revenue to range between $14.725 billion and $15.225 billion.
• Pharmacy Solutions: Expected to contribute $12.85 billion to $13.3 billion.
• Provider Services: Expected to contribute $1.875 billion to $1.925 billion.
• Recent M&A Integration: The company is actively integrating acquired assets from Amedisys and LHC Branches.
• Q1 2026 Contribution: These assets contributed $79 million in revenue and approximately $9 million in adjusted EBITDA in the first quarter of 2026.
• Full Year 2026 Outlook: Management expects these acquisitions to contribute approximately $30 million of EBITDA in year one.
• Strategic Divestiture: The company successfully closed the divestiture of its "Community Living business" (including home and community based waiver programs) on March 30, 2026, for $835 million (subject to adjustments). This transaction was part of a strategic pivot to focus on high-need, high-cost senior and specialty patients.
• Quality Metrics:
• Home Health Quality: Over 91% of branches are rated 4 stars or greater.
• Market Access: Added 4 exclusive ultra-narrow LDDs in Q1 2026, bringing the total to 153.
• Prescription Volume: Filled over 43 million prescriptions in 2025 across 175 pharmacies.
• Regulatory Headwinds: Management has quantified the impact of the Inflation Reduction Act (IRA), expecting a revenue impact of approximately $45 million per quarter for the remainder of 2026, totaling $175 million for the full year in Home and Community Pharmacy revenue.

4. Archetype and Conviction Stack

• Archetype: Margin Inflector.
• Rationale: The setup fits the "Margin Inflector" archetype because the company is executing a strategic pivot (divesting lower-margin Community Living assets) while integrating high-value acquisitions (Amedisys/LHC) that are expected to drive EBITDA growth ($30M contribution). The focus on "complex patients" and "high-need/high-cost" demographics (12% of population, 41% of spending) aligns with a business model designed to improve margins through specialized, higher-acuity care rather than volume-only growth.
• Valuation Context:
• Forward Consensus EPS: FY1 (2026) is $1.67773; FY2 (2027) is $2.11303.
• Implied Growth: The consensus suggests a significant earnings expansion from FY1 to FY2, supporting the "inflector" narrative where operational leverage and M&A synergies begin to materialize in the bottom line.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro tailwind).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm revenue ranges, EBITDA targets, and specific M&A integration progress.
• Structural Quality: Moderate to High. The "Forming Coil" state suggests a healthy consolidation. The current ATR of 3.1% indicates the stock is active but not overheated.
• Setup Readiness: Partial. The coil is "forming," meaning the setup is live but requires a breakout to become a confirmed "Actionable" trade.
• Rerating Potential: Moderate. The successful divestiture and clear path to EBITDA accretion from acquisitions provide a fundamental catalyst for multiple expansion if the price structure breaks out.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate the Case:
• Fundamental Deterioration: If the Amedisys/LHC integration fails to meet the $30M EBITDA target or if the IRA impact exceeds the $175M guidance, the "Margin Inflector" thesis would be compromised.
• What Would Strengthen the Case:
• Price Action: A confirmed breakout above the resistance level with volume, confirming the "active" status of the coil.
• Fundamental Execution: Management raising guidance for the full-year EBITDA range ($795M–$825M) or confirming that the $30M EBITDA contribution from acquisitions is on track ahead of schedule.
• Gaps in Evidence:
• Breakout Level: The specific resistance level to watch for a confirmed breakout is not explicitly stated, though it is implied to be the top of the current consolidation range.
• Debt/Capital Structure: While revenue and EBITDA are detailed, specific details on the debt load post-divestiture or the exact use of the $835M proceeds are not detailed in the provided evidence snippets.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Successful divestiture of Community Living business closing March 2026 for $835M; Management guidance for $30M EBITDA contribution from Amedisys/LHC integration in 2026; Strong quality metrics with 91% of home health branches rated 4 stars or greater. Sizing hint: Position size should reflect the "forming" nature of the coil; smaller initial size with add-on on confirmed breakout. Expected path: Price consolidates within the current range while management executes the integration of acquired assets; a breakout occurs once the market prices in the certainty of the EBITDA accretion. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.